Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Johannesburg Stock Exchange  >  Aspen Pharmacare Holdings Limited    APNJ   ZAE000066692

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Aspen Pharmacare : to buy remaining AstraZeneca anaesthetic rights for up to $766 million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 09:11am CET
A man walks past a sign at an AstraZeneca site in Macclesfield

AstraZeneca (>> AstraZeneca) said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group (>> Aspen Pharmacare Holdings Limited) for up to $766 million (579.86 million pounds), a year after Aspen bought the rights outside the United States.

AstraZeneca (>> AstraZeneca) said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group (>> Aspen Pharmacare Holdings Limited) for up to $766 million (579.86 million pounds), a year after Aspen bought the rights outside the United States.

The British group said it would continue to manufacture and supply the seven medicines - Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest - for a transition period of up to five years.

"Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas," said AstraZeneca executive Mark Mallon.

AstraZeneca is focusing on oncology, cardiovascular and metabolic diseases and respiratory treatments.

It said the deal, which comprises an upfront $555 million and performance related payments of up to $211 million, did not change its financial guidance for 2017.

(Reporting by Paul Sandle; editing by Jason Neely)

Stocks treated in this article : Aspen Pharmacare Holdings Limited, AstraZeneca
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASPEN PHARMACARE HOLDINGS
11/10 ASPEN PHARMACARE : cover story/paradise papers. THE APPLE OF ASPEN'S EYE
11/03 ASPEN PHARMACARE : found fit and healthy to finalise AstraZeneca deal
11/03 ASPEN PHARMACARE : found fit and healthy to finalise AstraZeneca deal
11/02 ASPEN PHARMACARE : completes acquisition of AstraZenecas anaesthetics portfolio
10/16 ASPEN PHARMACARE : UK anti-trust regulator investigates SA’s Aspen Pharmac..
10/13 ASPEN PHARMACARE : UK anti-trust regulator investigates South Africa's Aspen Pha..
10/06 Aspen and Equity probes halt
10/04 ASPEN PHARMACARE HOLDINGS LIMITED : ex-dividend day for annual dividend
09/18 ASPEN PHARMACARE : Hits & Misses. Hits. Tshabalala leads Standard alone but SA b..
09/16 Aspen Pharmacare posts 46% profit jump
More news
News from SeekingAlpha
11/22 Aspen Pharmacare Holdings (APNHY) Investor Presentation - Slideshow
05/17 Aspen Pharmacare Has Continued To Grow And Branch Out
2016 Wobbles Aside, Small Pharma Shares Broadly On The Up In 2015
2015 Sector's Smaller Players Show The Way
2015 OPPORTUNITIES AND RISKS IN THE BIOTE : 2 Companies In South Africa
Financials ( ZAR)
Sales 2018 46 259 M
EBIT 2018 11 704 M
Net income 2018 6 174 M
Debt 2018 41 592 M
Yield 2018 1,08%
P/E ratio 2018 20,23
P/E ratio 2019 16,01
EV / Sales 2018 4,01x
EV / Sales 2019 3,65x
Capitalization 144 B
Chart ASPEN PHARMACARE HOLDINGS
Duration : Period :
Aspen Pharmacare Holdings  Technical Analysis Chart | APNJ | ZAE000066692 | 4-Traders
Technical analysis trends ASPEN PHARMACARE HOLDINGS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 336  ZAR
Spread / Average Target 6,8%
EPS Revisions
Managers
NameTitle
Stephen Bradley Saad Group Chief Executive Officer & Executive Director
Douglas Dlamini Chairman
Lorraine Hill Group Operating Officer
Sean Capazorio Group Finance Officer
Michael Guy Attridge Executive Director & Group Deputy CEO
Sector and Competitors